Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Jorge Sabbaga"'
Autor:
Antonio Hugo José Fróes Marques Campos, Luciana Campi Auresco, Lidiane Vieira Marins, Paulo Henrique do Amor Divino, Jorge Sabbaga, Paulo Marcelo Hoff
Publikováno v:
Surgical and Experimental Pathology, Vol 7, Iss 1, Pp 1-13 (2024)
Abstract Predictive biomarkers of response to therapy are fundamental for the personalized therapeutic management of patients with colorectal carcinoma (CRC). The main predictive biomarkers related to CRC are the mismatch repair proteins/microsatelli
Externí odkaz:
https://doaj.org/article/89327d664cc64d7bbb01289872ffe404
Autor:
Fernanda Capareli, Frederico Costa, Jack A. Tuszynski, Micelange C. Sousa, Yone de C. Setogute, Pablo D. Lima, Luciana Carvalho, Elizabeth Santos, Brenda P. Gumz, Jorge Sabbaga, Tiago B. deCastria, Denis L. Jardim, Daniela Freitas, Natally Horvat, Regis O. F. Bezerra, Leonardo Testagrossa, Tiago Costa, Tatiana Zanesco, Antonio F. Iemma, Ghassan K. Abou‐Alfa
Publikováno v:
Cancer Medicine, Vol 12, Iss 11, Pp 12402-12412 (2023)
Abstract Background Patients with advanced hepatocellular carcinoma (HCC) and poor liver function lack effective systemic therapies. Low‐energy electromagnetic fields (EMFs) can influence cell biological processes via non‐thermal effects and may
Externí odkaz:
https://doaj.org/article/e607313da1734bf38413f03a8853d977
Autor:
Angelita Habr-Gama, Guilherme Pagin São Julião, Cinthia D. Ortega, Bruna Borba Vailati, Sergio Araujo, Thiago Jorge, Jorge Sabbaga, Gustavo L. Rossi, Renata D’Alpino, Fabio Roberto Kater, Patricia Bailão Aguilar, Adrian Mattacheo, Rodrigo Oliva Perez, Latin American Rectal Cancer Consortium (LARCC)
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background Neoadjuvant chemoradiation(nCRT) has been considered the preferred initial treatment strategy for distal rectal cancer. Advantages of this approach include improved local control after radical surgery but also the opportunity for
Externí odkaz:
https://doaj.org/article/74090b8a4d1e45b7b7d3d268dc73bd94
Autor:
Leonardo Gomes da Fonseca, Guilherme Nader Marta, Maria Ignez Freitas Melro Braghiroli, Aline Lopes Chagas, Flair Jose Carrilho, Paulo Marcelo Hoff, Jorge Sabbaga
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)
Abstract Background Before the targeted therapies era, cytotoxic chemotherapy (CCT) was an option for advanced hepatocellular carcinoma (HCC), even with the lack of supporting evidence. Since the last decade, sorafenib has been established as the fir
Externí odkaz:
https://doaj.org/article/f651009f98cb4a878e3cf8f6ed6aeb2f
Autor:
Guilherme Nader Marta, Leonardo G. da Fonseca, Maria Ignez Braghiroli, Fernando Moura, Paulo M. Hoff, Jorge Sabbaga
Publikováno v:
Clinics, Vol 76 (2021)
OBJECTIVES: To evaluate the efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma (HCC). METHODS: We analyzed data from a cohort of patients with advanced HCC treated using systemic treatment according to the loc
Externí odkaz:
https://doaj.org/article/95db7a37cf154a989acb8cc5cdbfe5d6
Autor:
Daniel M. Girardi, Mariana A. de Lima, Gabriel C. B. Pereira, Marcelo V. Negrão, Rossana V. M. López, Fernanda C. Capareli, Jorge Sabbaga, Paulo Marcelo G. Hoff
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)
Abstract Background Treatment of localized gastric cancer (LGC) consists of surgical resection followed by adjuvant treatment. Both chemoradiation (CRT) and chemotherapy (CT) regimens have shown benefit in survival outcomes versus observation. Howeve
Externí odkaz:
https://doaj.org/article/76bb3fdc7ade44489835116eec73b541
Autor:
Franciele H. Knebel, Fabiana Bettoni, Leonardo G. da Fonseca, Anamaria A. Camargo, Jorge Sabbaga, Denis L. Jardim
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Background: Anti-EGFR antibodies are a standard care for advanced KRAS-wild type colorectal cancers. Circulating tumor DNA (ctDNA) monitoring during therapy can detect emergence of KRAS mutant clones and early resistance to therapy.Case Presentation:
Externí odkaz:
https://doaj.org/article/a4b9c81e2f4d41679ba68db65c0e065e
Publikováno v:
Clinics and Practice, Vol 4, Iss 1 (2014)
A 55-year old man was treated with sunitinib 50 mg/day for 4 weeks on and 2 weeks off, as a first-line therapy for metastatic renal cell carcinoma. During the fourth week of the first cycle, he was admitted to the Emergency Department with abdominal
Externí odkaz:
https://doaj.org/article/8cf354113e654ca6995ff9038cd504f4
Autor:
Camila B Xavier, Rudinei Link, Leonília Abreu, Fabiana Bettoni, Fabiane Marson, Pedro A F Galante, Cibele Masotti, Mariane T Amano, Vinicius de Molla, Anamaria A Camargo, Paula F Asprino, Jorge Sabbaga
Publikováno v:
The Oncologist.
Objective Li-Fraumeni syndrome (LFS) is a pan-cancer predisposition syndrome caused by germline pathogenic variants in the gene TP53. The interpretation of TP53 variants in clinical scenarios outside the classic LFS criteria may be challenging. Here,
Autor:
Anamaria A. Camargo, Rodrigo Barreiro, Pedro A. F. Galante, Paula Fontes Asprino, Jorge Sabbaga, Benedito Mauro Rossi, Maria Isabel Achatz, Fabiana Bettoni
Publikováno v:
The Journal of Pathology. 256:214-222
MUTYH encodes a glycosylase involved in the base excision repair of DNA. Biallelic pathogenic germline variants in MUTYH cause an autosomal recessive condition known as MUTYH-associated adenomatous polyposis and consequently increase the risk of colo